X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dishman Pharma Fact Sheet, Dishman Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dishman Pharma Fact Sheet   (DHPH)

Here is the latest financial fact sheet of Dishman Pharma. For more details, see the Dishman Pharma quarterly results and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

DISHMAN PHARMA Price History

Price Rs 301.1
Mkt Cap Rs m 48,588
Vol '000 460.5
P/E X 25.1
P/CF X 17.3
EPS (TTM) Rs 12.0
% ch % 2.9
No. of shares m 161.39
% ch week % 3.5
% ch 1-mth % -2.4
% ch 12-mth % 96.4
52 week H/L Rs 346.3/127.6
(As on May 29, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DISHMAN PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
DISHMAN PHARMA EQUITY SHARE DATA
High Rs107122107183374 
Low Rs35423983129 
Sales per share (Unadj.) Rs139.3157.7171.7196.9197.8 
Earnings per share (Unadj.) Rs7.012.413.514.821.2 
Diluted earnings per shareRs3.56.26.87.410.6 
Cash flow per share (Unadj.) Rs16.522.827.033.534.7 
Dividends per share (Unadj.) Rs1.201.201.202.002.00 
Adj. dividends per shareRs0.600.600.601.001.00 
Dividend yield (eoy) %1.71.51.61.50.8 
Book value per share (Unadj.) Rs115.3128.2146.4153.4179.9 
Adj. book value per shareRs57.764.173.276.789.9 
Shares outstanding (eoy) m80.6980.6980.6980.6980.69 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.50.50.40.71.3 
Avg P/E ratio x10.16.65.48.911.9 
P/CF ratio (eoy) x4.33.62.74.07.2 
Price / Book Value ratio x0.60.60.50.91.4 
Dividend payout %17.19.78.913.59.4 
Avg Mkt Cap Rs m5,7296,6175,90210,69120,306 
No. of employees `0001.01.10.90.90.8 
Total wages/salary Rs m2,9413,5094,1234,2325,355 
Avg. sales/employee Rs Th11,541.312,059.014,848.018,430.919,252.7 
Avg. wages/employee Rs Th3,019.63,326.24,419.44,909.66,459.5 
Avg. net profit/employee Rs Th582.8950.61,171.21,389.92,064.1 
DISHMAN PHARMA INCOME DATA
Net Sales Rs m11,24112,72213,85315,88715,961 
Other income Rs m129178249869265 
Total revenues Rs m11,37012,90014,10216,75716,226 
Gross profit Rs m2,2452,9013,3213,1284,103 
Depreciation Rs m7658381,0861,5071,091 
Interest Rs m729788921897944 
Profit before tax Rs m8791,4531,5641,5932,334 
Minority Interest Rs m00000 
Prior Period Items Rs m00001 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m312450471394624 
Profit after tax Rs m5681,0031,0931,1981,711 
Gross profit margin %20.022.824.019.725.7 
Effective tax rate %35.431.030.124.826.7 
Net profit margin %5.07.97.97.510.7 
DISHMAN PHARMA BALANCE SHEET DATA
Current assets Rs m6,2396,7338,24510,13511,018 
Current liabilities Rs m6,5477,1279,02811,0489,517 
Net working cap to sales %-2.7-3.1-5.7-5.79.4 
Current ratio x1.00.90.90.91.2 
Inventory Days Days8797112103110 
Debtors Days Days6121385035 
Net fixed assets Rs m14,39114,57915,71715,82716,304 
Share capital Rs m161161161161161 
"Free" reserves Rs m8,2259,05110,03111,16712,907 
Net worth Rs m9,30710,34511,81312,37814,516 
Long term debt Rs m5,1214,3364,1213,3024,189 
Total assets Rs m22,49022,91126,27728,08929,805 
Interest coverage x2.22.82.72.83.5 
Debt to equity ratio x0.60.40.30.30.3 
Sales to assets ratio x0.50.60.50.60.5 
Return on assets %5.87.87.77.58.9 
Return on equity %6.19.79.39.711.8 
Return on capital %11.115.315.615.917.5 
Exports to sales %30.328.327.822.624.8 
Imports to sales %7.24.76.35.63.7 
Exports (fob) Rs m3,4043,5953,8553,5983,956 
Imports (cif) Rs m806599869891596 
Fx inflow Rs m3,9744,2103,9664,5764,952 
Fx outflow Rs m905695954974697 
Net fx Rs m3,0693,5153,0113,6014,255 
DISHMAN PHARMA CASH FLOW
From Operations Rs m 1,536 1,651 3,445 2,937 2,786 
From Investments Rs m -1,040 -1,173 -2,568 -1,581 -1,529 
From Financial Activity Rs m -680 -502 -741 -1,420 -941 
Net Cashflow Rs m -185 -23 136 -64 316 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 61.4%
Foreign collaborators 0.0%
Indian inst/Mut Fund 3.7%
FIIs 12.7%
ADR/GDR 0.0%
Free float 22.1%
Shareholders 46,261
Pledged promoter(s) holding 35.8%
 

Company Information

REGD OFF Bhadr-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad - 380 009
E-MAIL tushar.shah@dishmangroup.com WEB www.dishmangroup.com
TELEPHONE (079) 2644 3053 FAX (079) 2642 0198
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Comp., LBS Marg, Mumbai-78
AUDITOR Deloitte Haskins & Sells
CHM: Janmejay R. Vyas (MD) COMP SEC: Tushar D. Shah YEAR OF INC: 1983 BSE CODE: 532526 FV (Rs): 2 DIV YIELD (%): 0.3

More Pharmaceuticals Company Fact Sheets:   FULFORD INDIA  ELDER PHARMA  ALKEM LABORATORIES  J.B.CHEMICALS  DR. REDDYS LAB  

Compare DISHMAN PHARMA With:   FULFORD INDIA  ELDER PHARMA  ALKEM LABORATORIES  J.B.CHEMICALS  DR. REDDYS LAB  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Share Markets End the Week on a Dull Note(RoundUp)

Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS